SHR 1316Alternative Names: HTI-1088
Latest Information Update: 19 May 2017
Price : $50
At a glance
- Originator Atridia; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CD274 antigen inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Apr 2017 Atridia plans a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia (NCT02934412)
- 31 Dec 2015 Preclinical trials in Solid tumours in Australia (Parenteral)